PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Clinical trials for PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) explained in plain language.
Never miss a new study
Get alerted when new PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) trials appear
Sign up with your email to follow new studies for PRIMARY IMMUNE THROMBOCYTOPENIA (ITP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo aims to keep platelet counts stable in ITP patients
Disease control OngoingThis study tests whether adding ianalumab to standard steroid treatment helps adults with primary immune thrombocytopenia (ITP) maintain a safe platelet count (≥30 G/L) longer. About 226 participants who recently responded to steroids will receive either ianalumab or a placebo al…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 12:03 UTC
-
New hope for ITP patients: experimental drug aims to boost platelets
Disease control OngoingThis study tests an experimental drug called ianalumab in adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. Participants have already tried steroids and another platelet-boosting drug. The goal is to…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 20, 2026 11:53 UTC